Immune checkpoint inhibitors (ICIs) are major weapons in the modern era of anticancer
therapy. Immune-related adverse events (irAEs) usually appear within the first three
months of ICI treatment [
[1]
], but some have been reported up to one year after the introduction of ICIs and sometimes
after the treatment has been stopped. A plateau in the survival curve is observable
for patients treated with ICIs after the third year, which can be prolonged to 10
years for some [
[2]
]. A new category of patients is therefore emerging, that can be called ‘long-term
survivors’ (LTS) [
[3]
]. The management of these patients is still unknown. The long-term follow-up for
ICI-treated patients should consider new irAEs possibly occurring after treatment
cessation and quality of life (Qol).To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.Ann Oncol. 2016; 27: 559-574
- Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.J Clin Orthod. 2015; 33: 1889-1894
- Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab.JAMA Oncol. 2019; 5: 1411-1420
- Validation of the Insomnia Severity Index as an outcome measure for insomnia research.Sleep Med. 2001; 2: 297-307
- International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12).J Natl Cancer Inst. 2017; 109
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.Ann Oncol. 2017; 28: iv119-iv142
- Cancer survivorship. Longo DL, editor.N Engl J Med. 2018; 379: 2438-2450
- French Endocrine Society Guidance on endocrine side effects of immunotherapy.Endocr Relat Canc. 2019; : G1-G18
- Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients.Expert Review of Quality of Life in Cancer Care. 2018; 3: 19-26
- The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life.J Cancer Surviv. 2020; 14: 363-376
- Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.Support Care Canc. 2020; 28: 3267-3278
Article info
Publication history
Published online: March 18, 2021
Accepted:
February 8,
2021
Received:
January 2,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
